# Efficacy and Safety of Intravenous Treatment of Tuberculosis

> **NCT04150367** · — · TERMINATED · sponsor: **Yuria-Pharm** · enrollment: 166 (actual)

## Conditions studied

- Tuberculosis, Pulmonary

## Interventions

- **DRUG:** Isoniazid
- **DRUG:** Rifampicin
- **DRUG:** Ethambutol
- **DRUG:** Rifampicin
- **DRUG:** Isoniazid
- **DRUG:** Ethambutol

## Key facts

- **NCT ID:** NCT04150367
- **Lead sponsor:** Yuria-Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-03
- **Primary completion:** 2018-07-14
- **Final completion:** 2018-07-14
- **Target enrollment:** 166 (ACTUAL)
- **Why stopped:** According to Sponsor decision.
- **Last updated:** 2019-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04150367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04150367, "Efficacy and Safety of Intravenous Treatment of Tuberculosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04150367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*